Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):173–180. doi: 10.1097/QAI.0b013e3182278c09

Table 4.

Log hormone levels and DM in HIV-infected participants*

FT Model
OR (95% CI)
FT Model: AM ONLY
OR (95% CI)
SHBG Model
OR (95% CI)
SHBG Model: AM ONLY
OR (95% CI)
Log hormone** 0.72 (0.37, 1.40) 0.39 (0.17, 0.92) 0.53 (0.26, 1.09) 0.83 (0.35, 1.94)
Age 1.06 (1.00, 1.12) 1.04 (0.97, 1.11) 1.07 (1.01, 1.14) 1.06 (0.99, 1.13)
Race (Black v. other) 2.60 (1.10, 6.11) 2.20 (0.74, 6.50) 3.07 (1.29, 7.27) 2.46 (0.83, 7.27)
Current CD4 ≥ 200 0.75 (0.19, 2.96) 1.43 (0.24, 8.68) 0.69 (0.18, 2.69) 0.98 (0.18, 5.28)
BMI 1.08 (0.94, 1.24) 1.05 (0.85, 1.29) 1.07 (0.93, 1.23) 1.04 (0.85, 1.28)
HCV-infected 1.20 (0.47, 3.08) 1.70 (0.51, 5.63) 1.61 (0.61, 4.23) 2.02 (0.62, 6.60)
Viral load ≥ 400 0.27 (0.09, 0.75) 0.24 (0.07, 0.87) 0.29 (0.10, 0.80) 0.24 (0.07, 0.89)
Ever stavudine therapy 4.53 (1.91, 10.76) 5.50 (1.77, 17.13) 4.10 (1.74, 9.64) 4.54 (1.55, 13.30)
Waist circumference 0.99 (0.94, 1.05) 0.99 (0.93, 1.07) 0.99 (0.94, 1.05) 1.00 (0.93, 1.07)
*

All models adjusted for log hormone, age, site, black race, BMI, HCV status, CD4, viral load, ever used d4T, and waist circumference

**

Odds ratio or β corresponds to each 1-log increase in either FT or SHBG